New OTC Medications Available With Special Formulations

October 13th 2015

This line of products provides OTC medications for those that need special formulations which is hard to come by in today's market.

GM Pharmaceuticals recently announced their new line of products dedicated to those who have celiac disease, diabetes, alcohol or acetaminophen intolerance, and/or sensitivities to dyes. The DayClear line of products will now include gluten, sugar, alcohol, acetaminophen, and dye free products for allergy relief, sinus pain and pressure, and cold, cough and flu relief. The idea for these products was inspired by GM pharmaceuticals owner, Odes Mitchell, whose son has celiac disease. In apress releaseto PRNewswire, Mitchell stated, “We created DayClear because we wanted my son, and anyone else with a sensitivity, to have an option."

This line of products provides OTC medications for those that need special formulations which is hard to come by in today’s market. One in every 133 Americans are diagnosed with Celiac disease, 29.1 million Americans have to monitor glucose due to diabetes, and 80,000 people each year head to the emergency room due to acetaminophen overdose. These products are marketed to these populations as well as those intolerant to dyes and alcohol. Current research seems to show that patients with cystic fibrosis or fibromyalgia may have increased risk of alcohol intolerance. Being that DayClear products are dye-free, the liquids are clear setting them apart from most OTC formulations. The pain reliever available in select formulations is choline salicylate. Caution should be used in those who are allergic to salicylates. Sweeteners used include sucralose, sodium saccharin, or sorbitol depending on the product.

The product line is currently not available in-store in all states but is being launched in Connecticut, Massachusetts, Maryland, New York, Rhode Island, Virginia and Delaware. It will be available nationwide via Amazon. For more information, visit:http://www.dayclear.com/products.html.

Related Content